Log in

Relevant bibliographies by topics / Platinum compounds Therapeutic use / Journal articles

To see the other types of publications on this topic, follow the link: Platinum compounds Therapeutic use.

Journal articles on the topic 'Platinum compounds Therapeutic use'

Author: Grafiati

Published: 4 June 2021

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Platinum compounds Therapeutic use.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Xiao, Xiao, James Trevor Oswald, Ting Wang, Weina Zhang, and Wenliang Li. "Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery." Current Medicinal Chemistry 27, no. 18 (June 3, 2020): 3055–78. http://dx.doi.org/10.2174/0929867325666181105115849.

Full text

Abstract:

As one of the leading and most important metal-based drugs, platinum-based pharmaceuticals are widely used in the treatment of solid malignancies. Despite significant side effects and acquired drug resistance have limited their clinical applications, platinum has shown strong inhibitory effects for a wide assortment of tumors. Drug delivery systems using emerging technologies such as liposomes, dendrimers, polymers, nanotubes and other nanocompositions, all show promise for the safe delivery of platinum-based compounds. Due to the specificity of nano-formulations; unwanted side-effects and dru

APA, Harvard, Vancouver, ISO, and other styles

2

Hassan Marouf, Bushra, and Mayyadah Mahmood Ali. "Prevention and Management of Platinum Compounds-Induced Neurotoxicity." Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 ) 1 (November 22, 2021): 102–9. http://dx.doi.org/10.54133/ajms.v1i.43.

Full text

Abstract:

Oncologists considered platinum-based medicines as potent cytotoxic agents. Despite their efficacy in combination chemotherapy regimens for many solid tumors, they have many substantial side effects that limit their use. There is no known prophylactic strategy for platinum drugs-induced neurotoxicity, which limit a therapeutic dose benefit. This review highlights the etiology of platinum-drugs-induced neuropathy, and covers the preventative and therapeutic options for cancer patients. It focuses on clinical studies conducted between 2010 and 2020. Loss of functional indications such as touch,

APA, Harvard, Vancouver, ISO, and other styles

3

Makovec, Tomaz. "Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy." Radiology and Oncology 53, no. 2 (March 28, 2019): 148–58. http://dx.doi.org/10.2478/raon-2019-0018.

Full text

Abstract:

AbstractBackgroundPlatinum-based anticancer drugs are widely used in the chemotherapy of human neoplasms. The major obstacle for the clinical use of this class of drugs is the development of resistance and toxicity. It is therefore very important to understand the chemical properties, transport and metabolic pathways and mechanism of actions of these compounds. There is a large body of evidence that therapeutic and toxic effects of platinum drugs on cells are not only a consequence of covalent adducts formation between platinum complexes and DNA but also with RNA and many proteins. These proce

APA, Harvard, Vancouver, ISO, and other styles

4

Jurgens, Sophie, Fritz E. Kuhn, and Angela Casini. "Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives." Current Medicinal Chemistry 25, no. 4 (February 12, 2018): 437–61. http://dx.doi.org/10.2174/0929867324666170529125229.

Full text

Abstract:

Background: The inherent problems accompanying chemotherapy necessitate the development of new anticancer approaches. The development of compounds that can disrupt cancerous cellular machinery by novel mechanisms, via interactions with proteins and non-canonical DNA structures (e.g. G-quadruplexes), as well as by alteration of the intracellular redox balance, is nowadays focus of intense research. In this context, organometallic compounds of the noble metals Pt and Au have become prominent experimental therapeutic agents. This review provides an overview of the Pt(II) and Au(III) cyclometalate

APA, Harvard, Vancouver, ISO, and other styles

5

Roszczenko, Piotr, Olga Klaudia Szewczyk, Robert Czarnomysy, Krzysztof Bielawski, and Anna Bielawska. "Biosynthesized Gold, Silver, Palladium, Platinum, Copper, and Other Transition Metal Nanoparticles." Pharmaceutics 14, no. 11 (October 25, 2022): 2286. http://dx.doi.org/10.3390/pharmaceutics14112286.

Full text

Abstract:

Nanomedicine is a potential provider of novel therapeutic and diagnostic routes of treatment. Considering the development of multidrug resistance in pathogenic bacteria and the commonness of cancer, novel approaches are being sought for the safe and efficient synthesis of new nanoparticles, which have multifaceted applications in medicine. Unfortunately, the chemical synthesis of nanoparticles raises justified environmental concerns. A significant problem in their widespread use is also the toxicity of compounds that maintain nanoparticle stability, which significantly limits their clinical us

APA, Harvard, Vancouver, ISO, and other styles

6

Wimberger, Pauline, Barbara Klink, Konrad Gruetzmann, Julian Puppe, Daniel Klotz, Evelin Schroeck, Jan Dominik Kuhlmann, and Sarah Schott. "The activity of the conjugated antimetabolite 5-FdU-ECyd against platinum-resistant ovarian cancer." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e17077-e17077. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e17077.

Full text

Abstract:

e17077 Background: Primary or secondary resistance to platinum-based chemotherapy is an important clinical challenge in the treatment of ovarian cancer (OC) and limits survival. Therefore, the development of innovative drugs against platinum resistance is urgently needed. Our therapeutic concept is based on the conjugation of two chemotherapeutic compounds to a monotherapeutic pro-drug, which is taken up by cancer cells and is subsequently cleaved into several active cytostatic metabolites. Our in vitro study evaluates the effects of the conjugated antimetabolite 5-FdU-ECyd, consisting of 2-de

APA, Harvard, Vancouver, ISO, and other styles

7

Maiorano, Brigida Anna, Ugo De Giorgi, Davide Ciardiello, Giovanni Schinzari, Antonio Cisternino, Giampaolo Tortora, and Evaristo Maiello. "Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day." Biomedicines 10, no. 2 (February 9, 2022): 411. http://dx.doi.org/10.3390/biomedicines10020411.

Full text

Abstract:

Background: In advanced bladder cancer (BCa), platinum-based chemotherapy represents the first-choice treatment. In the last ten years, immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape of many solid tumors. Our review aims to summarize the main findings regarding the clinical use of ICIs in advanced BCa. Methods: We searched PubMed, Embase, and Cochrane databases, and conference abstracts from international congresses (ASCO, ESMO, ASCO GU) for clinical trials, focusing on ICIs as monotherapy and combinations in metastatic BCa. Results: 18 studies were identified. ICIs

APA, Harvard, Vancouver, ISO, and other styles

8

Marcu, Loredana G. "Gender and Sex-Related Differences in Normal Tissue Effects Induced by Platinum Compounds." Pharmaceuticals 15, no. 2 (February 20, 2022): 255. http://dx.doi.org/10.3390/ph15020255.

Full text

Abstract:

Gender medicine in the field of oncology is an under-researched area, despite the existing evidence towards gender-dependent response to therapy and treatment-induced adverse effects. Oncological treatment aims to fulfil its main goal of achieving high tumour control by also protecting normal tissue from acute or chronic damage. Chemotherapy is an important component of cancer treatment, with a large number of drugs being currently in clinical use. Cisplatin is one of the most commonly employed chemotherapeutic agents, used either as a sole drug or in combination with other agents. Cisplatin-i

APA, Harvard, Vancouver, ISO, and other styles

9

Faraoni, Isabella, and Grazia Graziani. "Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors." Cancers 10, no. 12 (December 4, 2018): 487. http://dx.doi.org/10.3390/cancers10120487.

Full text

Abstract:

Inhibition of poly(ADP-ribose) polymerase (PARP) activity induces synthetic lethality in mutated BRCA1/2 cancers by selectively targeting tumor cells that fail to repair DNA double strand breaks (DSBs). Clinical studies have confirmed the validity of the synthetic lethality approach and four different PARP inhibitors (PARPi; olaparib, rucaparib, niraparib and talazoparib) have been approved as monotherapies for BRCA-mutated or platinum-sensitive recurrent ovarian cancer and/or for BRCA-mutated HER2-negative metastatic breast cancer. PARPi therapeutic efficacy is higher against tumors harboring

APA, Harvard, Vancouver, ISO, and other styles

10

Krasnopolsky, Yu, D. Pylypenko, and G. Grigoryeva. "NANOMEDICINE IN ANTICANCER THERAPY." Bulletin of the National Technical University "KhPI". Series: Chemistry, Chemical Technology and Ecology 1, no. 7 (December 30, 2022): 3–13. http://dx.doi.org/10.20998/2079-0821.2022.01.

Full text

Abstract:

The use of liposomal nanoparticles as a drug delivery system today is a promising area of modern nanopharmacology, in particular in the development of antitumor drugs. Liposomal forms of antitumor active pharmaceutical ingredients are characterized by reduced toxicity, stability, and increased antitumor activity of nanoparticle-encapsulated antitumor agent, prolonged action of the drug. Commercially available liposomal anticancer drugs are passively targeted drugs that accumulate in cells by passive diffusion in tumor cells due to the EPR effect of the vascular system. This review presents da

APA, Harvard, Vancouver, ISO, and other styles

11

Varela-Castillo, O., P. Cordero, G. Gutiérrez-Iglesias, I. Palma, I. Rubio-Gayosso, E. Meaney, I. Ramirez-Sanchez, F. Villarreal, G. Ceballos, and N. Najera. "CHARACTERIZATION OF THE CYTOTOXIC EFFECTS OF THE COMBINATION OF CISPLATIN AND FLAVANOL (-)-EPICATECHIN ON HUMAN LUNG CANCER CELL LINE A549. AN ISOBOLOGRAPHIC APPROACH." Experimental Oncology 40, no. 1 (March 22, 2018): 19–23. http://dx.doi.org/10.31768/2312-8852.2018.40(1):19-23.

Full text

Abstract:

Background: Among malignancies, lung cancer is a leading cause of death. Platinum-based therapeutic compounds used to treat lung cancer have not been able to increase the survival of patients and such compounds have a high incidence of adverse and toxic effects. It has been proposed that flavonoids such as catechins may significantly reduce the risk of developing cancer, alongside with other health benefits. The aim of this work was to determine the effect of (-)-epicatechin, the main flavanol found in cocoa, on the proliferation of the lung non-small cell adenocarcinoma cancer cell line A549,

APA, Harvard, Vancouver, ISO, and other styles

12

P., Pramila, Anju Abraham, Sunita Pawar, Vibha Bafna, and Monika S. Bansal. "TO STUDY THE THERAPEUTIC MANAGEMENT, DRUG RELATED PROBLEMS AND CONCOMITANT USE OF DRUGSIN PATIENTS WITH CANCER." International Journal of Pharmacy and Pharmaceutical Sciences 9, no. 6 (June 1, 2017): 139. http://dx.doi.org/10.22159/ijpps.2017v9i6.18207.

Full text

Abstract:

Objective: To study the prescribing patterns of chemotherapeutic drugs, concomitant drugs and to determine the drug-related problems in cancer patients.Methods: A prospective and retrospective observational study was conducted over a period of 6 mo in a tertiary care teaching hospital, Pune after ethical approval and informed consent. Patients were then interviewed for patient information like demographics, treatment, and associated drug related problems using specially designed proforma and then required data was introduced in Microsoft excel spreadsheets.Results: Out of 60 patients 50 were e

APA, Harvard, Vancouver, ISO, and other styles

13

González-García, J., B. Alonso-Alvarez, GJ Nazco-Casariego, N. Batista-López, and F. Guttiérrez-Nicolás. "Plasma levels of trastuzumab in gastric cancer: Case report." Journal of Oncology Pharmacy Practice 23, no. 8 (September 23, 2016): 635–37. http://dx.doi.org/10.1177/1078155216670228.

Full text

Abstract:

Introduction The use of trastuzumab with a fluoropyrimidine and platinum compound is currently the standard first-line treatment of patients with metastatic HER2-positive gastric cancer, but it appears that serum levels of trastuzumab determine the clinical effectiveness of this treatment, affecting progression-free survival and overall survival. Case report We report the case of a patient with metastatic HER2-positivegastric cancer, receiving XELOX (fluoropyrimidine and oxaliplatin) plus trastuzumab at standard doses, who presented sub-therapeutic serum levels during the first two treatment c

APA, Harvard, Vancouver, ISO, and other styles

14

Dasari, Shaloam, Sylvianne Njiki, Ariane Mbemi, Clement G. Yedjou, and Paul B. Tchounwou. "Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy." International Journal of Molecular Sciences 23, no. 3 (January 28, 2022): 1532. http://dx.doi.org/10.3390/ijms23031532.

Full text

Abstract:

Cisplatin and other platinum-based drugs, such as carboplatin, ormaplatin, and oxaliplatin, have been widely used to treat a multitude of human cancers. However, a considerable proportion of patients often relapse due to drug resistance and/or toxicity to multiple organs including the liver, kidneys, gastrointestinal tract, and the cardiovascular, hematologic, and nervous systems. In this study, we sought to provide a comprehensive review of the current state of the science highlighting the use of cisplatin in cancer therapy, with a special emphasis on its molecular mechanisms of action, and t

APA, Harvard, Vancouver, ISO, and other styles

15

Lothstein, Leonard, Judith Soberman, Deanna Parke, Jatin Gandhi, Trevor Sweatman, and Tiffany Seagroves. "Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo." Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 28, no. 5 (December 10, 2020): 451–65. http://dx.doi.org/10.3727/096504020x15898794315356.

Full text

Abstract:

Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds. Multidrug therapies achieve pathological cure rates of only 2040%, a consequence of drug resistance and cumulative dose limitations necessitated by the reversible cardiotoxic effects of drug therapy. Safer and more effective treatments for TNBC are required to achieve durable therapeutic responses. This study describes the mechanistic analyses of the novel anthracycline, pivarubicin,

APA, Harvard, Vancouver, ISO, and other styles

16

Barr, Ronald D., Dawn Chalmers, Sonja De Pauw, William Furlong, Sheila Weitzman, and David Feeny. "Health-Related Quality of Life in Survivors of Wilms’ Tumor and Advanced Neuroblastoma: A Cross-Sectional Study." Journal of Clinical Oncology 18, no. 18 (September 18, 2000): 3280–87. http://dx.doi.org/10.1200/jco.2000.18.18.3280.

Full text

Abstract:

PURPOSE: In pediatric oncology, Wilms’ tumor and advanced neuroblastoma represent opposite ends of the spectra of survival probability and therapeutic intensity. Consequently, it was envisaged that survivors of Wilms’ tumor would enjoy better health status and health-related quality of life (HRQL) than survivors of advanced neuroblastoma. PATIENTS AND METHODS: Health status questionnaires were sent to the parents of all eligible children and to the children themselves if they were ≥ 8 years of age. Responses were received from 84% of 93 eligible families. Responses were converted by establishe

APA, Harvard, Vancouver, ISO, and other styles

17

Prasad, Sahdeo, Dan DuBourdieu, Ajay Srivastava, Prafulla Kumar, and Rajiv Lall. "Metal–Curcumin Complexes in Therapeutics: An Approach to Enhance Pharmacological Effects of Curcumin." International Journal of Molecular Sciences 22, no. 13 (June 30, 2021): 7094. http://dx.doi.org/10.3390/ijms22137094.

Full text

Abstract:

Curcumin, an active component of the rhizome turmeric, has gained much attention as a plant-based compound with pleiotropic pharmacological properties. It possesses anti-inflammatory, antioxidant, hypoglycemic, antimicrobial, neuroprotective, and immunomodulatory activities. However, the health-promoting utility of curcumin is constrained due to its hydrophobic nature, water insolubility, poor bioavailability, rapid metabolism, and systemic elimination. Therefore, an innovative stride was taken, and complexes of metals with curcumin have been synthesized. Curcumin usually reacts with metals th

APA, Harvard, Vancouver, ISO, and other styles

18

Bossi, P., D. Parolini, C. Bergamini, L. D. Locati, E. Orlandi, M. Franceschini, M. Palazzi, P. Olmi, P. Potepan, and L. Licitra. "TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 6046. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.6046.

Full text

Abstract:

6046 Background: Recent meta-analysis showed better event free survival in LANPC with induction CT. In head and neck cancer, docetaxel, cisplatin and 5 FU (TPF) induction chemotherapy led to survival gain over cisplatin and 5FU alone. We studied feasibility and activity of TPF induction CT followed by cCTRT in LANPC. Methods: From October 2004 to May 2008, 45 pts with LANPC were treated at our Institution with 2 to 4 cycles (median 3) of induction TPF (docetaxel 75 mg/sm and cisplatin 75 mg/sm on day 1, and 5-FU 750 mg/sm/day ci for 96 hrs. Prophylactic ciprofloxacin was administered for 10 da

APA, Harvard, Vancouver, ISO, and other styles

19

Bryde, Susanne, and Anton IPM de Kroon. "Nanocapsules of platinum anticancer drugs: development towards therapeutic use." Future Medicinal Chemistry 1, no. 8 (November 2009): 1467–80. http://dx.doi.org/10.4155/fmc.09.112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Soejima, Takashi, and Kei-ji Iwatsuki. "Innovative Use of Palladium Compounds To Selectively Detect Live Enterobacteriaceae in Milk by PCR." Applied and Environmental Microbiology 82, no. 23 (September 23, 2016): 6930–41. http://dx.doi.org/10.1128/aem.01613-16.

Full text

Abstract:

ABSTRACTEthidium monoazide and propidium monoazide (EMA and PMA) have been used in combination with PCR for more than a decade to facilitate the discrimination of live and dead bacteria (LD discrimination). These methods, however, require many laborious procedures, including the use of a darkroom. Here, we demonstrate an innovative use of palladium compounds involving lower limits of detection and quantification of targeted live cells, fewer laborious procedures, lower costs, and potentially higher-throughput analysis than the use of EMA and PMA. We have also recently reported platinum compoun

APA, Harvard, Vancouver, ISO, and other styles

21

Woźniak, Katarzyna, and Zofia Walter. "Induction of DNA-Protein Cross-Links by Platinum Compounds." Zeitschrift für Naturforschung C 55, no. 9-10 (October 1, 2000): 731–36. http://dx.doi.org/10.1515/znc-2000-9-1010.

Full text

Abstract:

Abstract The differences between cis- and trans-diamminedichloroplatinum II (DDP) in forming DNA-protein cross-links in isolated human lymphocytes were investigated. Both cis- and trans-DDP can induce DNA-protein cross-links. We show that cis-DDP forms complexes between DNA and proteins faster than trans-DDP. This results from an increase in the quantity of DNA and platinum together with an increase in drug concentration. Under the same conditions trans-DDP causes a decrease in DNA-forming complexes with proteins. After a 12 h incubation of lymphocytes we observe a similar level of DNA in DNA-

APA, Harvard, Vancouver, ISO, and other styles

22

Rébé, Cédric, Lucie Demontoux, Thomas Pilot, and François Ghiringhelli. "Platinum Derivatives Effects on Anticancer Immune Response." Biomolecules 10, no. 1 (December 20, 2019): 13. http://dx.doi.org/10.3390/biom10010013.

Full text

Abstract:

Along with surgery and radiotherapy, chemotherapeutic agents belong to the therapeutic arsenal in cancer treatment. In addition to their direct cytotoxic effects, these agents also impact the host immune system, which might enhance or counteract their antitumor activity. The platinum derivative compounds family, mainly composed of carboplatin, cisplatin and oxaliplatin, belongs to the chemotherapeutical arsenal used in numerous cancer types. Here, we will focus on the effects of these molecules on antitumor immune response. These compounds can induce or not immunogenic cell death (ICD), and so

APA, Harvard, Vancouver, ISO, and other styles

23

Reedijk, Jan. "Increased understanding of platinum anticancer chemistry." Pure and Applied Chemistry 83, no. 9 (March 31, 2011): 1709–19. http://dx.doi.org/10.1351/pac-con-10-11-03.

Full text

Abstract:

The development of a few worldwide routinely used Pt(II) coordination compounds is described from a mechanistic point of view and related to the molecular aspects of Pt-DNA binding. Mechanistic knowledge developed from these studies is applied nowadays for the design and synthesis of new bifunctional and trifunctional compounds, aimed for use as improved anticancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

24

Farrell, Nicholas P. "Preclinical perspectives on the use of platinum compounds in cancer chemotherapy." Seminars in Oncology 31 (December 2004): 1–9. http://dx.doi.org/10.1053/j.seminoncol.2004.11.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Maillard, Maud, Félicien Le Louedec, Fabienne Thomas, and Etienne Chatelut. "Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review." Expert Opinion on Drug Metabolism & Toxicology 16, no. 10 (October 2, 2020): 907–25. http://dx.doi.org/10.1080/17425255.2020.1789590.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Domínguez-Jurado, Elena, Francisco J. Cimas, José Antonio Castro-Osma, Alberto Juan, Agustín Lara-Sánchez, Antonio Rodríguez-Diéguez, Alexandr Shafir, Alberto Ocaña, and Carlos Alonso-Moreno. "Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer." Pharmaceutics 13, no. 10 (September 26, 2021): 1559. http://dx.doi.org/10.3390/pharmaceutics13101559.

Full text

Abstract:

Despite some limitations such as long-term side effects or the potential presence of intrinsic or acquired resistance, platinum compounds are key therapeutic components for the treatment of several solid tumors. To overcome these limitations, maintaining the same efficacy, organometallic ruthenium(II) compounds have been proposed as a viable alternative to platinum agents as they have a more favorable toxicity profile and represent an ideal template for both, high-throughput and rational drug design. To support the preclinical development of bis-phoshino-amine ruthenium compounds in the treatm

APA, Harvard, Vancouver, ISO, and other styles

27

Boussaad, Ibrahim, Andriana Kotini, Emily K. Dolezal, Stephen Nimer, and Eirini P. Papapetrou. "An iPSC-Based Model Of MDS For Phenotype-Driven Gene and Drug Discovery." Blood 122, no. 21 (November 15, 2013): 859. http://dx.doi.org/10.1182/blood.v122.21.859.859.

Full text

Abstract:

Abstract Despite past and ongoing research efforts, the pathogenetic mechanisms of MDS remain far from understood sufficiently to point to single genes or molecular pathways as putative targets for generation of better mouse models or drug development. In lack of clear targets, the manipulation of disease-associated phenotypes may at present be the best opportunity for disease study and therapeutic intervention. Furthermore, because cellular phenotypes are more proximal to molecular disease mechanisms than phenotypes seen at the level of the tissue or organism (i.e. the murine or human hematop

APA, Harvard, Vancouver, ISO, and other styles

28

Turkson, James, Shumin Zhang, Jay Palmer, Heidi Kay, Joseph Stanko, Linda B. Mora, Said Sebti, Hua Yu, and Richard Jove. "Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity." Molecular Cancer Therapeutics 3, no. 12 (December 1, 2004): 1533–42. http://dx.doi.org/10.1158/1535-7163.1533.3.12.

Full text

Abstract:

Abstract DNA-alkylating agents that are platinum complexes induce apoptotic responses and have wide application in cancer therapy. The potential for platinum compounds to modulate signal transduction events that contribute to their therapeutic outcome has not been extensively examined. Among the signal transducer and activator of transcription (STAT) proteins, Stat3 activity is frequently up-regulated in many human tumors. Various lines of evidence have established a causal role for aberrant Stat3 activity in malignant transformation and provided validation for its targeting in the development

APA, Harvard, Vancouver, ISO, and other styles

29

Romano, Alberto, Michele Antonio Capozza, Stefano Mastrangelo, Palma Maurizi, Silvia Triarico, Rolando Rolesi, Giorgio Attinà, Anna Rita Fetoni, and Antonio Ruggiero. "Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer." Cancers 12, no. 5 (May 17, 2020): 1266. http://dx.doi.org/10.3390/cancers12051266.

Full text

Abstract:

Platinum compounds are a group of chemotherapeutic agents included in many pediatric and adult oncologic treatment protocols. The main platinum compounds are cisplatin, carboplatin, and oxaliplatin. Their use in clinical practice has greatly improved long-term survival of pediatric patients, but they also cause some toxic effects: ototoxicity, myelosuppression, nephrotoxicity, and neurotoxicity. Hearing damage is one of the main toxic effects of platinum compounds, and it derives from the degeneration of hair cells of the ear, which, not having self-renewal capacity, cannot reconstitute themse

APA, Harvard, Vancouver, ISO, and other styles

30

Ali, Mayyadah Mahmood, and Tavga Ahmed Aziz. "Toxic Effect of Platinum Compounds: Molecular Mechanisms of Toxicity." Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 ) 1 (October 30, 2021): 81–88. http://dx.doi.org/10.54133/ajms.v1i.32.

Full text

Abstract:

Despite their effectiveness as a crucial component of combination chemotherapy regimens against solid tumors, platinum compounds have many serious side effects that limit their use. This review article focuses on the various toxic effects of platinum compounds in cancer patients and the mechanisms of toxicity associated with each of these toxic effects. It also describes the future directions for developing novel platinum compounds, using both animal and human studies. The reference lists of relevant publications were included after searching the Google and Google Scholar databases, PubMed, an

APA, Harvard, Vancouver, ISO, and other styles

31

Adokoh, Christian K. "Therapeutic potential of dithiocarbamate supported gold compounds." RSC Advances 10, no. 5 (2020): 2975–88. http://dx.doi.org/10.1039/c9ra09682e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Samochocka, K., and M. Czauderna. "Use of INAA to study the biodistribution of platinum compounds in animals." Journal of Radioanalytical and Nuclear Chemistry Letters 106, no. 3 (August 1986): 153–57. http://dx.doi.org/10.1007/bf02166785.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kushner, Brian H., Amy Budnick, Kim Kramer, Shakeel Modak, and Nai-Kong V. Cheung. "Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma." Cancer 107, no. 2 (2006): 417–22. http://dx.doi.org/10.1002/cncr.22004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Herman, Terence S., Beverly A. Teicher, Lynn Van Ummersen, and Laura S. Collins. "Synthesis and testing of new platinum-based compounds for use with hyperthermia." International Journal of Radiation Oncology*Biology*Physics 13 (October 1987): 165–66. http://dx.doi.org/10.1016/0360-3016(87)91161-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Charignon, Elsa, Mathilde Bouché, Caroline Clave-Darcissac, Georges Dahm, Gabriel Ichim, Anthony Clotagatide, Hichem C. Mertani, et al. "In Cellulo Evaluation of the Therapeutic Potential of NHC Platinum Compounds in Metastatic Cutaneous Melanoma." International Journal of Molecular Sciences 21, no. 21 (October 22, 2020): 7826. http://dx.doi.org/10.3390/ijms21217826.

Full text

Abstract:

We describe here the evaluation of the cytotoxic efficacy of two platinum (II) complexes bearing an N-heterocyclic carbene (NHC) ligand, a pyridine ligand and bromide or iodide ligands on a panel of human metastatic cutaneous melanoma cell lines representing different genetic subsets including BRAF-inhibitor-resistant cell lines, namely A375, SK-MEL-28, MeWo, HMCB, A375-R, SK-MEL-5-R and 501MEL-R. Cisplatin and dacarbazine were also studied for comparison purposes. Remarkably, the iodine-labelled Pt-NHC complex strongly inhibited proliferation of all tested melanoma cells after 1-h exposure, l

APA, Harvard, Vancouver, ISO, and other styles

36

Schweer, David, J. Robert McCorkle, Jurgen Rohr, Oleg V. Tsodikov, Frederick Ueland, and Jill Kolesar. "Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer." Biomedicines 9, no. 1 (January 12, 2021): 70. http://dx.doi.org/10.3390/biomedicines9010070.

Full text

Abstract:

Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-r

APA, Harvard, Vancouver, ISO, and other styles

37

Lam, Chui, and Kai Chow. "Use of New Therapeutic Compounds in Pregnancy with Renal Disease." Current Women's Health Reviews 1, no. 3 (November 1, 2005): 197–200. http://dx.doi.org/10.2174/157340405774575196.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Stojic, Isidora, Vladimir Zivkovic, Ivan Srejovic, Nevena Jeremic, Vladimir Jakovljevic, Dragan Djuric, and Slobodan Novokmet. "The Effects of Cisplatin and Its PT(II) Analogue on Oxidative Stress of Isolated Rat Heart/ Efekti Cisplatine I PT(II) Analoga Cisplatine Na Oksidacioni Stres Izolovanog Srca Pacova." Serbian Journal of Experimental and Clinical Research 17, no. 1 (March 1, 2016): 15–20. http://dx.doi.org/10.1515/sjecr-2015-0050.

Full text

Abstract:

Abstract To date, numerous platinum (II) complexes have been successfully used in the treatment of different types of cancer. Therapeutic platinum complexes are different in terms of their structure, chemical reactivity, solubility, pharmacokinetics and toxicity. The aim of our research was the evaluation of cardiotoxicity of dichloro-(ethylendiamine) platinum (II) in a model of isolated rat heart using the Langedorff technique. Oxidative stress was assessed by determination of superoxide anion radical, hydrogen peroxide, Thiobarbituric Acid Reactive Substances and nitric oxide levels from cor

APA, Harvard, Vancouver, ISO, and other styles

39

Buyana, Buhle, Tobeka Naki, Sibusiso Alven, and Blessing Atim Aderibigbe. "Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy." International Journal of Molecular Sciences 23, no. 19 (September 24, 2022): 11261. http://dx.doi.org/10.3390/ijms231911261.

Full text

Abstract:

Colorectal cancer is a common cancer in both men and women. Numerous studies on the therapeutic effectiveness of nanoparticles against colorectal cancer have been reported. Platinum treatments as well as other medications comprising of nanoparticles have been utilized. Drug resistance restricts the use of platinum medicines, despite their considerable efficacy against a variety of cancers. This review reports clinically licensed platinum medicines (cisplatin, carboplatin, and oxaliplatin) combined with various nanoparticles that have been evaluated for their therapeutic efficacy in the treatme

APA, Harvard, Vancouver, ISO, and other styles

40

Dag, Aydan, Manuela Callari, Hongxu Lu, and Martina H. Stenzel. "Modulating the cellular uptake of platinum drugs with glycopolymers." Polymer Chemistry 7, no. 5 (2016): 1031–36. http://dx.doi.org/10.1039/c5py01579k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Bernocchi, G., M. G. Bottone, V. M. Piccolini, V. Dal Bo, G. Santin, S. A. De Pascali, D. Migoni, and F. P. Fanizzi. "Developing Central Nervous System and Vulnerability to Platinum Compounds." Chemotherapy Research and Practice 2011 (February 15, 2011): 1–14. http://dx.doi.org/10.1155/2011/315418.

Full text

Abstract:

Comparative studies on the effects of the platinum complexes in use or in clinical trials are carried out in order to discover differences in the neurotoxic potential and the reversibility of neurotoxicity. In this paper, we summarized the current literature on neurotoxicity and chemoresistance of cisplatin (cisPt) and discussed our recent efforts on the interference of cisPt and a new platinum compound [Pt(O,O′-acac)(γ-acac)(DMS)] (PtAcacDMS), with high specific reactivity with sulphur ligands instead of nucleobases as cisPt, on some crucial events of rat postnatal cerebellum development. The

APA, Harvard, Vancouver, ISO, and other styles

42

Villalba, Jose M., Cristina Parrado, Monica Santos-Gonzalez, and Francisco J. Alcain. "Therapeutic use of coenzyme Q10and coenzyme Q10-related compounds and formulations." Expert Opinion on Investigational Drugs 19, no. 4 (March 31, 2010): 535–54. http://dx.doi.org/10.1517/13543781003727495.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Khokhlova, S. V., M. V. Cherkasova, N. F. Orel, S. V. Limareva, I. Ya Bazaeva, and V. A. Gorbunova. "WHICH PATIENTS WITH OVARIAN CANCER SHOWS THE COMBINATION OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN." Annals of the Russian academy of medical sciences 68, no. 11 (November 12, 2013): 115–21. http://dx.doi.org/10.15690/vramn.v68i11.852.

Full text

Abstract:

Given the high rate of recurrence of ovarian cancer, the search for new therapeutic strategies are topical issue. According to various studies the effectiveness of drug treatment relapse depends on the platinum-free interval, increasing in proportion to its duration. If therapy is platinum-resistant recurrent ovarian cancer is a standard approach, the treatment of platinum-sensitive recurrent algorithm is not fully defined. Comparison of platinum and non-platinum combinations revealed the advantage of combined platinum- treatment for patients with platinum-free interval of more than 6 months w

APA, Harvard, Vancouver, ISO, and other styles

44

Köberle, Beate, and Sarah Schoch. "Platinum Complexes in Colorectal Cancer and Other Solid Tumors." Cancers 13, no. 9 (April 25, 2021): 2073. http://dx.doi.org/10.3390/cancers13092073.

Full text

Abstract:

Cisplatin is one of the most commonly used drugs for the treatment of various solid neoplasms, including testicular, lung, ovarian, head and neck, and bladder cancers. Unfortunately, the therapeutic efficacy of cisplatin against colorectal cancer is poor. Various mechanisms appear to contribute to cisplatin resistance in cancer cells, including reduced drug accumulation, enhanced drug detoxification, modulation of DNA repair mechanisms, and finally alterations in cisplatin DNA damage signaling preventing apoptosis in cancer cells. Regarding colorectal cancer, defects in mismatch repair and alt

APA, Harvard, Vancouver, ISO, and other styles

45

Ronchi, Cristina L., Silviu Sbiera, Luitgard Kraus, Sebastian Wortmann, Sarah Johanssen, Patrick Adam, Holger S. Willenberg, Stefanie Hahner, Bruno Allolio, and Martin Fassnacht. "Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy." Endocrine-Related Cancer 16, no. 3 (September 2009): 907–18. http://dx.doi.org/10.1677/erc-08-0224.

Full text

Abstract:

Therapeutic progress in adrenocortical carcinoma (ACC) is severely hampered by its low incidence. Platinum-based chemotherapies are the most effective cytotoxic treatment regimens in ACC but response rates remain <50%. In other tumor entities, expression of excision repair cross complementing group 1 (ERCC1) predicts resistance to platinum compounds. Therefore, we correlated ERCC1 protein expression and clinical outcome. We have retrolectively established adrenal tissue microarrays and analyzed prospectively samples from 163 ACCs, 15 benign adrenal adenomas, and 8 normal adrenal glands by i

APA, Harvard, Vancouver, ISO, and other styles

46

Soejima, Takashi, Jun-ichi Minami, Jin-zhong Xiao, and Fumiaki Abe. "Innovative use of platinum compounds to selectively detect live microorganisms by polymerase chain reaction." Biotechnology and Bioengineering 113, no. 2 (August 19, 2015): 301–10. http://dx.doi.org/10.1002/bit.25711.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Szefler, Beata, Przemysław Czeleń, and Przemysław Krawczyk. "The Affinity of Carboplatin to B-Vitamins and Nucleobases." International Journal of Molecular Sciences 22, no. 7 (March 31, 2021): 3634. http://dx.doi.org/10.3390/ijms22073634.

Full text

Abstract:

Platinum compounds have found wide application in the treatment of various types of cancer and carboplatin is one of the main platinum-based drugs used as antitumor agents. The anticancer activity of carboplatin arises from interacting with DNA and inducing programmed cell death. However, such interactions may occur with other chemical compounds, such as vitamins containing aromatic rings with lone-pair orbitals, which reduces the anti-cancer effect of carboplatin. The most important aspect of the conducted research was related to the evaluation of carboplatin affinity to vitamins from the B g

APA, Harvard, Vancouver, ISO, and other styles

48

Venturella, Giuseppe, Valeria Ferraro, Fortunato Cirlincione, and Maria Letizia Gargano. "Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials." International Journal of Molecular Sciences 22, no. 2 (January 10, 2021): 634. http://dx.doi.org/10.3390/ijms22020634.

Full text

Abstract:

Medicinal mushrooms have important health benefits and exhibit a broad spectrum of pharmacological activities, including antiallergic, antibacterial, antifungal, anti-inflammatory, antioxidative, antiviral, cytotoxic, immunomodulating, antidepressive, antihyperlipidemic, antidiabetic, digestive, hepatoprotective, neuroprotective, nephroprotective, osteoprotective, and hypotensive activities. The growing interest in mycotherapy requires a strong commitment from the scientific community to expand clinical trials and to propose supplements of safe origin and genetic purity. Bioactive compounds of

APA, Harvard, Vancouver, ISO, and other styles

49

Venturella, Giuseppe, Valeria Ferraro, Fortunato Cirlincione, and Maria Letizia Gargano. "Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials." International Journal of Molecular Sciences 22, no. 2 (January 10, 2021): 634. http://dx.doi.org/10.3390/ijms22020634.

Full text

Abstract:

Medicinal mushrooms have important health benefits and exhibit a broad spectrum of pharmacological activities, including antiallergic, antibacterial, antifungal, anti-inflammatory, antioxidative, antiviral, cytotoxic, immunomodulating, antidepressive, antihyperlipidemic, antidiabetic, digestive, hepatoprotective, neuroprotective, nephroprotective, osteoprotective, and hypotensive activities. The growing interest in mycotherapy requires a strong commitment from the scientific community to expand clinical trials and to propose supplements of safe origin and genetic purity. Bioactive compounds of

APA, Harvard, Vancouver, ISO, and other styles

50

Shoji, Eto, Sato, Soma, Fukagawa, Tomabechi, Takatori, et al. "A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease." Healthcare 7, no. 3 (September 19, 2019): 109. http://dx.doi.org/10.3390/healthcare7030109.

Full text

Abstract:

Treatment beyond progressive disease (PD) is a concept that even after drugs become ineffective, their continued use is more beneficial for patients than their discontinuation. In recent years, a concept of bevacizumab beyond PD (BBP) has attracted attention in the treatment of various cancers, and the usefulness of this concept has been evaluated. BBP has been proven to prolong overall survival (OS) in recurrent colorectal cancer and progression-free survival (PFS) in recurrent breast and lung cancers. With regard to the treatment of ovarian cancer, the MITO16/MaNGO-OV2B study (the Multicente

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!